FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

773879000: Antineoplastic therapeutic role (role)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 31-Jan 2019. Module: SNOMED CT core module

Descriptions:

Id Description Lang Type Status Case? Module
3726859011 Antineoplastic therapeutic role en Synonym Active Entire term case insensitive SNOMED CT core module
3726860018 Antineoplastic therapeutic role (role) en Fully specified name Active Entire term case insensitive SNOMED CT core module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Antineoplastic therapeutic role Is a Therapeutic role true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing precisely triptorelin (as triptorelin acetate) 3 milligram/1 vial powder for conventional release suspension for injection Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely triptorelin 11.25 milligram/1 vial powder for conventional release suspension for injection Plays role False Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely triptorelin (as triptorelin acetate) 3.75 milligram/1 syringe powder for conventional release suspension for injection Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing triptorelin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only formestane (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing formestane Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only fulvestrant in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely fulvestrant 50 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Fulvestrant Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing fulvestrant Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing fulvestrant in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing letrozole Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only letrozole in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Letrozole Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely letrozole 2.5 milligram/1 each conventional release oral tablet Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing letrozole in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing leuprorelin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only leuprorelin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Leuprorelin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely leuprorelin acetate 7.5 milligram/1 milliliter conventional release suspension for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely leuprorelin acetate 20 milligram/1 milliliter conventional release suspension for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely leuprorelin acetate 120 milligram/1 milliliter conventional release suspension for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing leuprorelin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely leuprorelin acetate 11.25 milligram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely leuprorelin acetate 3.75 milligram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing megestrol Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only megestrol in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Megestrol Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely megestrol acetate 125 milligram/1 milliliter conventional release oral suspension (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely megestrol acetate 40 milligram/1 each conventional release oral tablet Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely megestrol acetate 160 milligram/1 each conventional release oral tablet Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely megestrol acetate 40 milligram/1 milliliter conventional release oral suspension Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely megestrol acetate 20 milligram/1 each conventional release oral tablet Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing megestrol in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only lenalidomide in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Lenalidomide Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely lenalidomide 10 milligram/1 each conventional release oral capsule Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing lenalidomide Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely lenalidomide 5 milligram/1 each conventional release oral capsule Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing lenalidomide in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely lenalidomide 20 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely lenalidomide 2.5 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely lenalidomide 25 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely lenalidomide 15 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing peginterferon alfa-2b Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing peginterferon alfa-2b in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Peginterferon alfa-2b Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 100 microgram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 80 microgram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 120 microgram/1 pen powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 50 microgram/1 pen powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 80 microgram/1 pen powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Peginterferon alfa-2a Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only peginterferon alfa-2a in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2a (as peginterferon alfa-2a) 270 microgram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2a (as peginterferon alfa-2a) 360 microgram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Ibritumomab tiuxetan Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ibritumomab tiuxetan Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only cyproterone in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Cyproterone Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely cyproterone acetate 100 milligram/1 each conventional release oral tablet Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely cyproterone acetate 50 milligram/1 each conventional release oral tablet Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing interferon alfa-2a Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing peginterferon alfa-2a in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only interferon alfa-2a in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Interferon alfa-2a Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing peginterferon alfa-2a Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing interferon alfa-2a in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing interferon alfa-2b Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only interferon alfa-2b in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only interferon alfa-2b in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only peginterferon alfa-2b in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Interferon alfa-2b Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2b 10 million unit/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2b 1 million unit/1 vial powder for conventional release solution for injection Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing interferon alfa-2b in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing interferon alfa-2b in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 50 microgram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 120 microgram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 150 microgram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 150 microgram/1 pen powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only interferon alfa-n1 (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing interferon alfa-n1 Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only interferon alfacon-1 in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only interferon alfacon-1 (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing interferon alfacon-1 Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing interferon alfacon-1 in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing interferon beta-1a Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing peginterferon beta-1a Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Peginterferon beta-1a Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only interferon beta-1a in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Interferon beta-1a Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon beta-1a 24 million unit/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon beta-1a 30 microgram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon beta-1a 30 microgram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing interferon beta-1a in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing interferon beta-1b Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only interferon beta-1b in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Interferon beta 1b Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon beta-1b 300 microgram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing interferon beta-1b in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier

Start Previous Page 13 of 26 Next End

This concept is not in any reference sets

Back to Start